Literature DB >> 22366771

The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system.

Franck Le Duff1, Aude Emmanuelle Develay, Julien Quetel, Pierre Lafay, Stéphane Schück, Christian Pradier, Philippe Robert.   

Abstract

In France, one of the aims of the current national Alzheimer's disease plan is to collect data from all memory centers (memory units, memory resource and research centers, independent neurologists) throughout the country. Here we describe the French Alzheimer Information System and present a 'snapshot' of the data collected throughout the country during the first year of operation. We analyzed all data transmitted by memory centers between January 2010 and December 2010. Each participating center is required to transmit information on patients to the French National Alzheimer dataBank (BNA). This involves completing a computer file containing 31 variables corresponding to a limited data set on AD (CIMA: Corpus minimum d'information Alzheimer). In 2010, the BNA received data from 320 memory centers relating to 199,113 consultations involving 118,776 patients. An analysis of the data shows that the initial MMSE (Mini Mental State Examination) mean score for patients in France was 16.8 points for Alzheimer's disease, 25.7 points for mild cognitive impairment, and 18.8 points for 'related disorders related disorders. The BNA will provide longitudinal data that can be used to assess the needs of individual local health areas and size specialized care provision in each regional health scheme. By contributing to the BNA, the memory centers enhance their clinical activity and help to advance knowledge in epidemiology and medical research in the important field of Alzheimer's disease and related dementias.

Entities:  

Mesh:

Year:  2012        PMID: 22366771     DOI: 10.3233/JAD-2012-111943

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

1.  Removal of Drugs for Alzheimer's Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA).

Authors:  Marie Herr; Joël Ankri; Capucine Diard; Anne Hiance-Delahaye
Journal:  Drugs Aging       Date:  2021-01-07       Impact factor: 3.923

2.  Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis.

Authors:  Alberto Serrano-Pozo; Georgina M Aldridge; Qiang Zhang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study.

Authors:  François Mouton-Liger; David Wallon; Anne-Cécile Troussière; Rachida Yatimi; Julien Dumurgier; Eloi Magnin; Vincent de la Sayette; Emannuelle Duron; Nathalie Philippi; Emilie Beaufils; Audrey Gabelle; Bernard Croisile; Philippe Robert; Florence Pasquier; Didier Hannequin; Jacques Hugon; Claire Paquet
Journal:  J Neurol       Date:  2013-10-27       Impact factor: 4.849

4.  Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design.

Authors:  Federica Ribaldi; Christian Chicherio; Daniele Altomare; Marta Martins; Szymon Tomczyk; Ileana Jelescu; Enrique Maturana; Max Scheffler; Sven Haller; Karl-Olof Lövblad; Michela Pievani; Valentina Garibotto; Matthias Kliegel; Giovanni B Frisoni
Journal:  Alzheimers Res Ther       Date:  2021-05-25       Impact factor: 6.982

5.  Early detection of memory impairment in people over 65 years old consulting at Health Examination Centers for the French health insurance: the EVATEM protocol.

Authors:  Christiane Vannier-Nitenberg; Virginie Dauphinot; Bienvenu Bongue; Catherine Sass; Isabelle Rouch; Olivier Beauchet; Pierre Krolak-Salmon; Bruno Fantino
Journal:  BMC Geriatr       Date:  2013-06-06       Impact factor: 3.921

6.  The mini mental state examination at the time of Alzheimer's disease and related disorders diagnosis, according to age, education, gender and place of residence: a cross-sectional study among the French National Alzheimer database.

Authors:  Christian Pradier; Charlotte Sakarovitch; Franck Le Duff; Richard Layese; Asya Metelkina; Sabine Anthony; Karim Tifratene; Philippe Robert
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

7.  Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study.

Authors:  Claire Paquet; Eloi Magnin; David Wallon; Anne-Cécile Troussière; Julien Dumurgier; Alain Jager; Frank Bellivier; Elodie Bouaziz-Amar; Frédéric Blanc; Emilie Beaufils; Carole Miguet-Alfonsi; Muriel Quillard; Susanna Schraen; Florence Pasquier; Didier Hannequin; Philippe Robert; Jacques Hugon; François Mouton-Liger
Journal:  Alzheimers Res Ther       Date:  2016-06-13       Impact factor: 6.982

8.  Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.

Authors:  Karim Tifratene; Valeria Manera; Roxane Fabre; Auriane Gros; Susanne Thummler; Christian Pradier; Philippe Robert; Renaud David
Journal:  Alzheimers Res Ther       Date:  2017-04-26       Impact factor: 6.982

9.  Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders.

Authors:  Virginie Dauphinot; Christelle Mouchoux; Sébastien Veillard; Floriane Delphin-Combe; Pierre Krolak-Salmon
Journal:  Alzheimers Res Ther       Date:  2017-08-01       Impact factor: 6.982

10.  Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study.

Authors:  A Mouton; F Blanc; A Gros; V Manera; R Fabre; E Sauleau; I Gomez-Luporsi; K Tifratene; L Friedman; S Thümmler; C Pradier; P H Robert; R David
Journal:  Alzheimers Res Ther       Date:  2018-09-12       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.